Sotagliflozin Rejected for T1D; Thyroid and COVID; Diabetes Drug Price Cut

The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease, said maker Lexicon Pharmaceuticals. The decision was expected following a negative FDA advisory committee review in October.

Over 40% of Americans say they are overweight, and 55% want to lose weight, according to a Gallup poll.

In a meta-analysis of 154 randomized controlled trials of people with overweight or obesity, tirzepatide (Mounjaro, Zepbound) was best at blood pressure, glucose, and weight reduction, while semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) reduced risk of major cardiac events. (eClinicalMedicine)

A systematic review delved into how SARS-CoV-2 infection impacts the thyroid. (Frontiers in Endocrinology)

“Both long and short-pouch gastric bypass surgeries are effective and safe for weight loss and remission of obesity-associated medical problems in patients with severe obesity and exhibited similar rates for remission of underlying diseases and endoscopic findings,” researchers concluded in a Scientific Reports retrospective study.

Some doctors’ offices are doing away with weight measurements, with concerns that the routine practice may be driving patients away. (New York Times)

Among 247 Asian adults ages 65 and older, those with sarcopenia, low muscle mass, and weak muscle strength had at least 27% higher circulating resistin concentrations — an adipose-derived hormone — than controls. (Journal of Clinical Endocrinology & Metabolism)

At the start of the new year, Merck plans to cut the list price of its diabetes drugs sitagliptin (Januvia) and sitagliptin/metformin (Janumet) “to align the list price more closely to the net price.” (Reuters via Yahoo! News)

At least 150 minutes of aerobic exercise per week was tied with clinically important reductions in waist circumference and measures of body fat, a meta-analysis of 166 trials of adults with overweight or obesity found. (JAMA Network Open)